[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:bcr-abl1-fusion-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BCR\u002FABL1 Fusion Gene",39,34,[8,16,22,29,35,42,49,55,61,67,73,79,85,91,97,104,110,115,121,127,133,139,145,151,157,163,169,175,181,187,193,199,205,211,217,224,231,237,243],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02981628","Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",[12],"Phase 2","RECRUITING","2026-08-03T00:52:47.662427Z","2026-07-05T05:32:16.771394Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",[12],"2026-08-26T02:18:33.598205Z","2026-06-06T00:48:49.516454Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06051409","A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)",[26],"Phase 3","2026-08-26T02:18:29.369233Z","2026-05-13T02:55:06.404671Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05007873","ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",[12],"2026-08-03T02:39:51.946262Z","2026-05-05T02:43:29.710118Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06308588","Phase I\u002FII Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[39],"Phase 1\u002FPhase 2","2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.682278Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT06401603","A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",[46],"Phase 1","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.388278Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06236724","Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",[12],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:29.199644Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06163430","A Phase 1\u002F2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)",[39],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.654539Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06629584","Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia",[12],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:28.480225Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07269470","Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[12],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:28.219978Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06152809","CIML NK Cells With Venetoclax for AML",[46],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06423911","Study of Olverembatinib (HQP1351) in Patients With CP-CML",[26],"2026-08-26T02:16:38.053590Z","2026-05-05T02:43:27.755425Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07250087","Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",[46],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:27.401585Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":102,"content_modified":103},"NCT04877522","Asciminib Roll-over Study",[101],"Phase 4","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.182842Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07040982","Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[46],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.099677Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":83,"content_modified":114},"NCT05304377","A Phase 1a\u002F1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia",[46],"2026-05-05T02:43:26.926295Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05535855","UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",[46],"2026-08-26T02:16:03.788292Z","2026-05-05T02:35:31.898196Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07224100","Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia\u002FLymphoma",[12],"2026-08-26T02:17:10.213717Z","2026-05-05T02:35:31.650647Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT01746836","Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",[12],"2026-08-26T02:19:12.219640Z","2026-04-29T02:57:57.143397Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT03595917","ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",[46],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.224482Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT02727803","Personalized NK Cell Therapy in CBT",[12],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.030294Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05857969","Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling",[46],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.220097Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[12],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT03630991","Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",[46],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.485890Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[12],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07354074","Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP",[12],"2026-08-26T02:16:49.565137Z","2026-07-19T19:36:05.137104Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07091019","A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy",[],"2026-08-26T02:18:27.904411Z","2026-07-05T03:45:20.248555Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT06297161","A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).",[],"2026-08-26T02:18:58.141497Z","2026-05-13T02:55:06.433451Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT07638007","Impact of Targeted Therapy on Cancer-Related Cognitive Impairment",[],"2026-08-26T02:15:09.079045Z","2026-06-14T18:39:22.257477Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors",[],"2026-08-26T02:15:21.365312Z","2026-05-13T02:55:06.119599Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT03589729","Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers",[12],"2026-08-26T02:15:34.659160Z","2026-04-29T02:57:57.071823Z",{"nct_id":218,"title":219,"phases":220,"status":221,"updated_at":222,"content_modified":223},"NCT02646839","KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL\u002FAML\u002FMDS Allo-HCT Children",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.966507Z",{"nct_id":225,"title":226,"phases":227,"status":228,"updated_at":229,"content_modified":230},"NCT04626024","Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T01:59:45.393638Z","2026-05-05T02:43:29.369086Z",{"nct_id":232,"title":233,"phases":234,"status":228,"updated_at":235,"content_modified":236},"NCT05143840","Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",[12],"2026-08-03T02:57:43.835765Z","2026-05-05T02:43:27.802908Z",{"nct_id":238,"title":239,"phases":240,"status":228,"updated_at":241,"content_modified":242},"NCT04872790","Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",[46],"2026-08-03T02:32:04.757108Z","2026-05-05T02:43:26.960917Z",{"nct_id":244,"title":245,"phases":246,"status":247,"updated_at":248,"content_modified":249},"NCT04835584","KRT-232 and TKI Study in Chronic Myeloid Leukemia",[39],"UNKNOWN","2026-08-03T02:38:34.966507Z","2026-04-29T02:57:57.100256Z"]